These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 11757206)

  • 21. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
    Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
    Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy of malignancy-associated hypercalcemia: 1983.
    Stewart AF
    Am J Med; 1983 Mar; 74(3):475-80. PubMed ID: 6219580
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of calcitonin and pamidronate for emergency treatment of malignant hypercalcemia.
    Sekine M; Takami H
    Oncol Rep; 1998; 5(1):197-9. PubMed ID: 9458321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hypercalcemia as an emergency].
    Rosenmund A
    Schweiz Med Wochenschr; 1993 Apr; 123(15):735-8. PubMed ID: 8488377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages.
    Nussbaum SR; Younger J; Vandepol CJ; Gagel RF; Zubler MA; Chapman R; Henderson IC; Mallette LE
    Am J Med; 1993 Sep; 95(3):297-304. PubMed ID: 8368227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypercalcemia of malignancy remains a clinically relevant problem.
    Van Poznak C
    Cancer J; 2006; 12(1):21-3. PubMed ID: 16613658
    [No Abstract]   [Full Text] [Related]  

  • 28. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
    Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
    Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypercalcaemia due to malignancy. Role of the kidney and treatment.
    Sleeboom HP; Bijvoet OL
    Contrib Nephrol; 1982; 33():178-96. PubMed ID: 6214375
    [No Abstract]   [Full Text] [Related]  

  • 30. Hypercalcemia: an evidence-based approach to clinical cases.
    Assadi F
    Iran J Kidney Dis; 2009 Apr; 3(2):71-9. PubMed ID: 19395781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newer agents for the treatment of malignant hypercalcemia.
    Kinirons MT
    Am J Med Sci; 1993 Jun; 305(6):403-6. PubMed ID: 8506902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tumoral hypercalcemia: physiopathology and treatment].
    Rizzoli R; Jung A; Bonjour JP
    Schweiz Med Wochenschr; 1985 Mar; 115(10):326-32. PubMed ID: 3157214
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Management of acute hypercalcemia.
    Bilezikian JP
    N Engl J Med; 1992 Apr; 326(18):1196-203. PubMed ID: 1532633
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathogenesis and management of cancer associated hypercalcaemia.
    Ralston SH
    Cancer Surv; 1994; 21():179-96. PubMed ID: 8564993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of cancer-related hypercalcemia: the role of gallium nitrate.
    Leyland-Jones B
    Semin Oncol; 2003 Apr; 30(2 Suppl 5):13-9. PubMed ID: 12776255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.
    ThiƩbaud D; Jacquet AF; Burckhardt P
    Arch Intern Med; 1990 Oct; 150(10):2125-8. PubMed ID: 2222097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Hypercalcemia therapy in malignant tumors].
    Bruntsch U
    MMW Munch Med Wochenschr; 1979 Jan; 121(1):16-8. PubMed ID: 152868
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
    Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy.
    Flores JF; Rude RK; Chapman RA; Belani CP; Chang AY; Pritchard JD; Hoff JV
    Cancer; 1994 May; 73(10):2527-34. PubMed ID: 8174049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Medical treatment of malignant hypercalcemia].
    Eto S; Nakano Y; Okada Y
    Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.